These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 18321622)

  • 1. Analysis of in vivo mutation data can inform cancer risk assessment.
    Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
    Preston RJ
    Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
    McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
    Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects.
    Shipp A; Lawrence G; Gentry R; McDonald T; Bartow H; Bounds J; Macdonald N; Clewell H; Allen B; Van Landingham C
    Crit Rev Toxicol; 2006; 36(6-7):481-608. PubMed ID: 16973444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adjustment factor for mode-of-action uncertainty with dual-mode carcinogens: the case of naphthalene-induced nasal tumors in rats.
    Bogen KT
    Risk Anal; 2008 Aug; 28(4):1033-51. PubMed ID: 18564993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
    Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
    Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.
    Gaylor DW; Swirsky Gold L
    Regul Toxicol Pharmacol; 1998 Dec; 28(3):222-5. PubMed ID: 10049793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating genotoxicity data to identify a mode of action and its application in estimating cancer risk at low doses: A case study involving carbon tetrachloride.
    Eastmond DA
    Environ Mol Mutagen; 2008 Mar; 49(2):132-41. PubMed ID: 18213651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of genetic toxicology information for risk assessment.
    Dearfield KL; Moore MM
    Environ Mol Mutagen; 2005 Dec; 46(4):236-45. PubMed ID: 16258925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of the mode of action framework for mutagenic carcinogens case study II: chromium (VI).
    McCarroll N; Keshava N; Chen J; Akerman G; Kligerman A; Rinde E
    Environ Mol Mutagen; 2010 Mar; 51(2):89-111. PubMed ID: 19708067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic data and cancer risk assessment: the need for quantitative molecular endpoints.
    Preston RJ
    Environ Mol Mutagen; 2005; 45(2-3):214-21. PubMed ID: 15645441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.S. EPA's IRIS assessment of 2-butoxyethanol: the relationship of noncancer to cancer effects.
    Gift JS
    Toxicol Lett; 2005 Mar; 156(1):163-78. PubMed ID: 15705494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
    Kitchin KT; Conolly R
    Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple method for quantitative risk assessment of non-threshold carcinogens based on the dose descriptor T25.
    Sanner T; Dybing E; Willems MI; Kroese ED
    Pharmacol Toxicol; 2001 Jun; 88(6):331-41. PubMed ID: 11453374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action in relevance of rodent liver tumors to human cancer risk.
    Holsapple MP; Pitot HC; Cohen SM; Boobis AR; Klaunig JE; Pastoor T; Dellarco VL; Dragan YP
    Toxicol Sci; 2006 Jan; 89(1):51-6. PubMed ID: 16221960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to cancer assessment in EPA's Integrated Risk Information System.
    Gehlhaus MW; Gift JS; Hogan KA; Kopylev L; Schlosser PM; Kadry AR
    Toxicol Appl Pharmacol; 2011 Jul; 254(2):170-80. PubMed ID: 21034767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postulated carbon tetrachloride mode of action: a review.
    Manibusan MK; Odin M; Eastmond DA
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(3):185-209. PubMed ID: 17763046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
    Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens.
    Butterworth BE
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):9-23. PubMed ID: 16530901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.